Bristol-Myers Squibb Co. BMY

Bristol-Myers Squibb Company se dedica al descubrimiento, desarrollo, licenciamiento, fabricación, comercialización, distribución y venta de productos biofarmacéuticos. Los productos farmacéuticos de la compañía incluyen medicamentos sintetizados químicamente, o moléculas pequeñas, y productos producidos a partir de procesos biológicos, llamados biológicos. Los medicamentos de moléculas pequeñas se administran por vía oral en forma de píldora o tableta. Los biológicos se administran a los pacientes a través de inyecciones o por infusión. Sus productos incluyen Revlimid, Abraxane, Reblozyl, Inrebic, Onureg, Zeposia, Vidaza, Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Reyataz y Sustiva Franchise. Ofrece productos para una variedad de clases terapéuticas, que incluyen oncología, inmunología, cardiovascular y fibrosis. Sus productos se venden a mayoristas, farmacias minoristas, hospitales, entidades gubernamentales y profesionales médicos en todo el mundo. Sus subsidiarias son Celgene Corp y MyoKardia, Inc.

Con 16 acciones de BMY (USD 976,22) habrías recibido USD 40,32 en dividendos en los últimos 12 meses.

• Zacks Investment Research 2 oct

  Agios' Growth Story Hinges on Mitapivat's Commercial Expansion

  Agios Pharmaceuticals' mitapivat-based drugs (Pyrukynd and Aqvesme) generated $44.7 million in Q2 2026 revenue, up 259% year-over-year, driven by early thalassemia adoption. However, the discontinuation of pipeline drug tebapivat and intensifying competition from Novo Nordisk's etavopivat in sickle cell disease have made the company heavily dependent on mitapivat's commercial success.

  

• GlobeNewswire Inc. 1 oct

  Autoimmune CAR T Safety Events Reshape Rheumatologist Sentiment, but Autologous CAR T Retains Lead, According to Spherix Global Insights

  Following trial pauses by Novartis and Bristol Myers Squibb due to safety concerns, rheumatologist confidence in autologous CAR T dropped significantly from 7.5 to 5.2 on a 10-point scale. Despite this, autologous CAR T retained its lead among immune reset modalities at 49% preference. Systemic sclerosis emerged as the clearest near-term opportunity, while delivery infrastructure and safety evidence are now critical differentiators for market adoption.

  

• Zacks Investment Research 30 sept

  Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know

  Bristol Myers Squibb (BMY) is receiving significant investor attention. The stock has declined 6.1% over the past month, underperforming the S&P 500. However, the company maintains a Zacks Rank #2 (Buy) rating based on positive earnings estimate revisions and strong recent performance, with the stock trading at a valuation discount to peers. BMY beat consensus estimates in the last four quarters with an EPS surprise of +28.3% and revenue surprise of +11.15%.

  

• GlobeNewswire Inc. 30 sept

  Bone Metastasis in Solid Tumors Market Insights, Epidemiology, and 7MM Forecast - 2036 | Precision Oncology and Radiopharmaceuticals Unlock New Growth Opportunities

  The bone metastasis in solid tumors market is expected to expand from 2026-2036 across seven major markets, driven by rising cancer survival rates, improved diagnostics, and growing demand for targeted therapies and radiopharmaceuticals. The market is characterized by established treatments like denosumab and zoledronic acid, with emerging therapies including cabozantinib and radioligand treatments. Key unmet needs include limited disease-modifying therapies, persistent skeletal complications, and lack of validated biomarkers for treatment selection.

  

• GlobeNewswire Inc. 30 sept

  Head and Neck Squamous Cell Carcinoma (HNSCC) - Market Insights, Epidemiology, and Market Forecast - 2036 | Set to Reach $2.56 Billion as HPV-Targeted Vaccines Reshape Care

  The HNSCC market is projected to grow from $850 million in 2025 to $2.56 billion by 2036 (10.5% CAGR), driven by HPV-targeted vaccines, checkpoint inhibitors, and biomarker-led patient selection. The US will remain the largest market at $2.082 billion. Key therapies include KEYTRUDA and OPDIVO, with emerging candidates like petosemtamab and amivantamab showing promise in clinical development.